Clinical trial NCT04516369: Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Official title: An Open-label, Single-arm Study to Provide Efficacy and Safety Data of Voretigene Neparvovec Administered as Subretinal Injection in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Biallelic RPE65 Mutation-associated Retinal Dystrophy
Keywords: LTW888
voretigene neparvovec
Biallelic RPE65 mutation-associated retinal dystrophy
Japanese patients
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2020-08-18
Enrollment: 4
Sex: ALL
Minimum age (years): 4
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to provide safety and efficacy data for voretigene neparvovec, administered as subretinal injection, in Japanese patients with biallelic RPE65 mutation-associated retinal dystrophy.

Detailed description: This is an open-label, single-arm study to evaluate the safety and efficacy of bilateral subretinal administration of voretigene neparvovec in Japanese patients with biallelic RPE65 mutation-associated retinal dystrophy. Assessments will include full-field light sensitivity threshold testing, visual fields, visual acuity, vector shedding, immunogenicity and adverse events. Participants will be monitored for 5 years after treatment.

Eligibility criteria: Inclusion Criteria:

* Japanese participants with biallelic RPE65 mutation-associated retinal dystrophy; molecular diagnosis of RPE65 mutation must be confirmed by a Novartis designated laboratory in Japan.
* Age four years or older.
* Visual acuity worse than 20/60 (both eyes) and/or visual field less than 20 degrees in any meridian as measured by a III4e isopter or equivalent (both eyes).
* Sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/ or ophthalmoscopy. Must have either:

  * An area of retina within the posterior pole of \> 100 µm thickness shown on OCT, or
  * ≥ 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole, or
  * Remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent

Exclusion Criteria:

* Any prior participation in a study in which a gene therapy vector was administered.
* Participation in a clinical study with an investigational drug in the past 6 months from screening visit.
* Known hypersensitivity to any of the study treatments including excipients or to medications planned for use in the peri-operative period.
* Unable to reliably perform the FST assessment.
* Use of retinoid compounds or precursors that could potentially interact with the biochemical activity of the RPE65 enzyme in the past 6 months from screening visit.
* Prior intraocular surgery within 6 months from screening visit.
* Prior use of any medicines that, in the opinion of the investigator, may have caused retinal damage (e.g., sildenafil or related compounds, hydroxychloroquine, chloroquine, thioridazine, any other retino-toxic compounds)
* Pre-existing eye conditions or complicating systemic diseases that would preclude the planned surgery or interfere with the interpretation of study. Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter ocular function.

Primary outcomes:
measure: Change from Baseline in full-field light sensitivity threshold
timeFrame: Baseline, Day 30, 90, 180, 270, and Year 1 after second eye injection
Secondary outcomes:
measure: Change from Baseline in visual field
timeFrame: Baseline, Day 14, 30, 90, 180, 270, and Year 1, 2, 3, 4, 5 after second eye injection
measure: Change from Baseline in macular threshold
timeFrame: Baseline, Day 14, 30, 90, 180, 270, and Year 1, 2, 3, 4, 5 after second eye injection
measure: Change from Baseline in visual acuity
timeFrame: Baseline, Day 1, and 3 after first eye injection; Day 1, 3, 14, 30, 90, 180, 270, and Year 1, 2, 3, 4, 5 after second eye injection
measure: Change from Baseline in FST for long-term period
timeFrame: Baseline, Year 2, 3, 4 and 5 after second eye injection
measure: Proportion of subject with the presence of vector shedding of voretigene neparvovec during the study period
timeFrame: Baseline, Day 0, 1 and 3 after first eye injection; Day 0, 1, 3, 14, 30, 90, 180, 270, and Year 1 after second eye injection
measure: Proportion of subject with the presence of immunogenicity of voretigene neparvovec during the study period
timeFrame: Baseline, Day 30, 90, 180, 270, and Year 1 after second eye injection
Other outcomes:
Locations:
city: Meguro-ku
country: Japan
facility: Novartis Investigative Site
state: Tokyo
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: